News

Fulvestrant bests anastrozole in advanced breast cancer

Publish date: December 18, 2014

 

AT SABCS 2014

References

The FIRST trial was funded by AstraZeneca. Dr. Robertson reported serving as a consultant to that company as well as Bayer HealthCare and receiving research funding from both companies along with Amgen and Novartis.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

SOFT trial endorses selective ovarian suppression in early breast cancer
MDedge Hematology and Oncology
VIDEO: Dr. Prudence Francis describes how SOFT results will change practice
MDedge Hematology and Oncology
VIDEO: What was the most interesting thing you learned at the meeting?
MDedge Hematology and Oncology
20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit
MDedge Hematology and Oncology
VIDEO: What have we learned about prevention of breast cancer from IBIS-1?
MDedge Hematology and Oncology
AI-induced symptoms don’t predict survival
MDedge Hematology and Oncology
Acupuncture beats gabapentin for hot flashes in RCT
MDedge Hematology and Oncology
Genetic test predicts 10-year risk of DCIS recurrence
MDedge Hematology and Oncology
Information and communication needs of Chinese American breast cancer patients: perspectives on survivorship care planning
MDedge Hematology and Oncology
Predictors of resolution in navigated patients with abnormal cancer screening tests
MDedge Hematology and Oncology